Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments.
Many advances have been made in the cardiovascular field in the last several decades. Among them is the progress completed to date on the heptapeptide member of the renin-angiotensin system (RAS), angiotensin-(1-7) [Ang-(1-7)]. The peptide's beneficial actions against pathophysiological processes, such as cardiac arrhythmia, heart failure, hypertension, renal disease, preeclampsia, and even cancer are continuously being uncovered. This review encompasses the pharmacology of Ang-(1-7) and expounds upon the peptide's potential as a therapeutic agent against pathological processes both within and outside the cardiovascular continuum.
Trask
Aaron J
AJ
The Hypertension and Vascular Research Center, Wake Forest University Health Science Center, Winston-Salem, North Carolina 27157, USA. atrask@wfubmc.edu
Ferrario
Carlos M
CM
D000803:Angiotensin I / Q000494:pharmacology* / Q000502:physiology / Q000627:therapeutic use; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects*; D002318:Cardiovascular Diseases / Q000188:drug therapy; D006321:Heart / Q000187:drug effects*; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D010446:Peptide Fragments / Q000494:pharmacology* / Q000502:physiology / Q000627:therapeutic use; D012084:Renin-Angiotensin System / Q000187:drug effects* / Q000502:physiology
D000959:Antihypertensive Agents; D010446:Peptide Fragments; D000803:Angiotensin I; C118790:angiotensin I (1-7)